A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Familial Chylomicronemia Syndrome
About this trial
This is an interventional treatment trial for Familial Chylomicronemia Syndrome focused on measuring FCS
Eligibility Criteria
Inclusion Criteria:
• Satisfactory completion of treatment with olezarsen in the index study (ISIS 678354-CS3, last dose as scheduled at Week 49) with an acceptable safety profile, per Investigator judgement.
Exclusion Criteria:
• Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the patient participating in or completing the study, including need for treatment with medications disallowed in the index study (ISIS 678354-CS3).
Sites / Locations
- Diabetes/Lipid Management & Research CenterRecruiting
- Excel Medical Clinical Trials, LLCRecruiting
- Department of PharmacyRecruiting
- University of Kansas Medical Center (KUMC)Recruiting
- CTSI Investigational PharmacyRecruiting
- Milstein HospitalRecruiting
- IDS CentralRecruiting
- Ecogene-21Recruiting
- Institute de Recherches Cliniques de MontrealRecruiting
- Nathalie Saint-PierreRecruiting
- Clinique des Maladies Lipidiques de Quebec Inc.Recruiting
- Groupement Hospitalier Est- Pharmacie Secteur Essais CliniqueRecruiting
- Hôpital BicêtreRecruiting
- Pharmacie Hopital de la ConceptionRecruiting
- Via Sergio Pansini 5Recruiting
- UOC di Farmacia AOUP PAOLO GIACCONERecruiting
- Azienda Ospedaliero Universitaria Policlinico Umberto IRecruiting
- Academisch Medisch Centrum Goederenontvangst Apotheek t.a.v. KenniscentrumRecruiting
- Oslo Hospital Pharmacy RikshospitaletRecruiting
- Hospital da Senhora da Oliveira GuimaraesRecruiting
- Dra Margarida Falcao Centro Hospitalar Lisboa Ocidental Hospital Egas MonizRecruiting
- Metabolicke centrum MURecruiting
- Hospital Clínic Barcelona C/ VillarroelRecruiting
- Hospital Universitario 12 de OctubreRecruiting
- Hospital Universitario Virgen del RocíoRecruiting
- Apokteket ABRecruiting
- Royal Manchester Children's HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Olezarsen
Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 153.